2023年7月17日

嵌入,代碼複製並粘貼到你的網站或者博客:< iframe幀邊緣= = " 620 "滾動=“1”高度src = " / /www.jdsupra.com/post/contentViewerEmbed.aspx?“汽車”fid = 674 db56f - 98 - f4 - 4411 a711 - 56 - a266eb6ead”風格= "邊境:2 px固體# ccc;overflow-x:隱藏!重要;溢出:隱藏;“寬度= " 100% " > < / iframe > 7月7日,2023年,消費者金融保護局(CFPB),美國衛生與人類服務部(度)和美國財政部(點)進行公開調查某些金融產品,如醫療信用卡分期貸款,消費者金融保護局被描述為“high-cos專業產品。“消費者金融保護局,哎,點聲稱這些產品往往是“推”在消費者和有效地提高常規醫療保健的成本,導致醫療債務增加。調查持續努力的一部分,消費者金融保護局調查醫療融資產品和醫療債務,以研究為基礎的局關於這些產品,消費者金融之前介紹的見解。消費者金融保護局,哎,點的請求從公眾和尋求評論的信息感興趣的有關金融產品用於支付醫療費用。評級機構表示,他們“尋求理解流行,自然,這些產品的影響,包括在不同的人口群體差異。機構也試圖了解這些產品的影響可能對病人和衛生保健係統。“專門機構請求信息:醫療產品市場融資,包括利息和費用成本醫療融資產品和進一步的信息”營銷,應用程序和審批流程。“消費者金融保護局表示,它也感興趣”趨勢的醫療支付產品使用,包括總優秀醫學信用卡消費者債務,醫療分期貸款,和其他醫療支付產品”,這將幫助這些機構有更多的了解如何使用這些產品。消費者對風險的理解這些產品。 The CFPB specifically identified “loss of medical bill negotiating power, aggressive debt collection practices, lawsuits, and loss of credit reporting protections.” Whether medical financing products “exacerbate existing issues in health care billing and collections.” The CFPB gave the example of how uninsured or out-of-network patients may be charged higher prices than negotiated by in-network providers and expressed concern that medical payment products may further enable this trend of charging such patients more. The incentives offered by medical financing companies to health care providers to promote medical payment products, such as revenue sharing, and how these incentives impact how the products are offered to patients. This public inquiry is consistent with the CFPB’s continued interest in these products and their impact on consumers. The comment period is open for 60 days until September 7, 2023.